Cefprozil monohydrate (CAS 121123-17-9)

Cefprozil monohydrate is a stabilized hydrate form of cefprozil, a broad-spectrum, second-generation cephalosporin antibiotic known for its efficacy in treating a variety of bacterial infections. This antibiotic works by targeting and inhibiting penicillin-binding proteins (PBPs), which are critical for the synthesis of bacterial cell walls. By binding to these proteins, cefprozil monohydrate disrupts the cell wall synthesis process, particularly the cross-linking of peptidoglycan chains, which compromises the structural integrity of the bacterial cell wall, leading to cell lysis and death. This mechanism makes it effective against a range of both Gram-positive and Gram-negative bacteria. In research settings, cefprozil monohydrate has been extensively studied to understand its pharmacological properties, including absorption, distribution, metabolism, and excretion (ADME), as well as its clinical efficacy and resistance patterns. These investigations help in optimizing dosing regimens and understanding the scope of bacterial resistance, thereby informing clinical strategies for its use in non-therapeutic investigative scenarios focused on bacterial pathogenesis and antibiotic action.